FLDM Fluidigm

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA.

Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT.

A live audio webcast will be available to investors and other interested parties by accessing the Investor Relations page of the Company’s website at . A recording will be archived and available on the Standard BioTools Investor Relations page at .

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: .

Patent and License Information: .

Trademarks: . Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact

David Holmes

Gilmartin Group LLC



EN
19/12/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fluidigm

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Standard BioTools Reports Second Quarter 2025 Financial Results

Standard BioTools Reports Second Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch